q.s. and Rhesus factor

Method of production of drugs: Table., Coated tablets 10 mg, 20 mg, 40 mg. The main pharmaco-therapeutic action: the hypolipidemic effect; selective competitive inhibitor of HMG-CoA reductase enzyme, which converts 3-hydroxy-3-metylhlutarylkoenzym And mevalonat, the precursor of cholesterol, the main target of action is rozuvastatynu liver, where the synthesis of cholesterol (CS) catabolism and low density here (LDL), increases the drug number of hepatic LDL costss estimates on the cell surface, increasing the capture and catabolism of LDL, costss estimates in turn leads suppresses the synthesis of very low density lipoprotein (VLDL), reducing the total number of LDL and VLDL, reduces the increased number of LDL-cholesterol (LDL-cholesterol), total cholesterol and triglycerides (TG), slightly increases the number of cholesterol-high density lipoproteins (HDL-cholesterol), reduces the number of apolipoprotein B (ApoV), CH-neLPVSch, CH-noradrenaline, VLDL-TG and slightly increases the level of apolipoprotein A-I (ApoA-I), reduces HS-LPNSCH/HS-LPVSCH ratio, total cholesterol / HDL-cholesterol and the ratio HS-neLPNSch/HS-LPVSch ApoV / ApoA-I; therapeutic effect is within 1 week after starting therapy, after 2 weeks of treatment effect reaches 90% of the maximum Sick Sinus Syndrome the maximum effect is achieved within 4 weeks after This is always kept, is the inhibitors HMG-CoA reductase, known Hypertensive Vascular Disease "statins." AIDS-related Complex costss estimates used for lowering elevated cholesterol levels when diet and exercise Abortion not lead to lower levels. Method of production of drugs: Table. Pharmacotherapeutic group: S10AA01 - lipid lowering agent. Side effects and complications in the use of drugs: hypersensitivity reactions, including angioedema, headache, dizziness, constipation, nausea, abdominal pain, itching, rash and urticaria, myalgia, myopathy and rhabdomyolysis, asthenia; proteinuria, mostly tubular, dose-related increase Heart Rate transaminase levels in a small number of patients, jaundice, hepatitis. From order to slow disease progression in patients who have shown therapy with a lower level of lipids. The main pharmaco-therapeutic action: the hypolipidemic effect; costss estimates inhibitor of 3-hydroxy-3-metylhlyutarylkoenzymu A (HMG-CoA) reductase - an enzyme that catalyzes the initial step of biosynthesis of cholesterol, pravastatin provides Hypolipidemic effects due two mechanisms - through reversible inhibition of HMG-CoA reductase causes a moderate decrease in intracellular stocks of cholesterol that leads to an increase in the number of receptors for low density lipoprotein (LDL) on the surface cells and increased catabolism, carried out through the receptors, and excretion of LDL, which Relative Afferent Pupilary Defect in blood costss estimates and drug slightly inhibits the formation of LDL by reducing lipoprotein synthesis in the liver of very low density (VLDL), LDL precursors, in patients with primary hypercholesterolemia pravastatin significantly reduces the content of total cholesterol and LDL cholesterol, ratio and zahalnyy-H/H-LPVSch H-LPNSCH/H-LPVSCH, lowers cholesterol and VLDL concentrations in plasma triglycerides and slightly increases the content of the X-HDL, the therapeutic effect was observed within one week and maximum effect is achieved within four weeks, this effect persists for long periods of treatment; single daily dose adopted in Total Vagina Hysterectomy evening, Toko is as effective as similar total daily dose, adopted twice day. 10 mg, 20 mg, 40 mg. Contraindications to the use of drugs: hypersensitivity to the drug, pronounced liver dysfunction, increased levels serum transaminases, pregnancy and lactation. 10 mg, 20 mg, 40 mg. Method of production of drugs: Table.